Bluesight on Twitter: "The 340B program is becoming a popular topic in the pharmacy world. In our latest blog, we discuss The Evolution of the 340B Program: From Cost Savings to Revenue
GlaxoSmithKline censured by EU over pay-for-delay deals | Financial Times